presentation.mkdn 14 KB

123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387
  1. ---
  2. title: Bioinformaticanalysis of complex, high-throughput genomic and epigenomic data in the context of $\mathsf{CD4}^{+}$ T-cell differentiation and diagnosis and treatment of transplant rejection
  3. author: |
  4. Ryan C. Thompson \
  5. Su Lab \
  6. The Scripps Research Institute
  7. date: October 24, 2019
  8. theme: Boadilla
  9. aspectratio: 169
  10. fontsize: 14pt
  11. ---
  12. ## Organ transplants are a life-saving treatment
  13. ::: incremental
  14. * 36,528 transplants performed in the USA in 2018[^organdonor]
  15. * 100 transplants every day!
  16. * Over 113,000 people on the national transplant waiting list as of
  17. July 2019
  18. :::
  19. [^organdonor]: [organdonor.gov](https://www.organdonor.gov/statistics-stories/statistics.html)
  20. ## Organ transplants are a life-saving treatment
  21. ![Organ donation statistics for the USA in 2018[^organdonor]](graphics/presentation/transplants-organ-CROP.pdf){ height=70% }
  22. ## Graft rejection is an adaptive immune response
  23. <!-- TODO: Need a graphic for this -->
  24. ::: incremental
  25. * The host's adaptive immune system identifies and attacks cells
  26. bearing non-self antigens
  27. * An allograft contains differnet genetic variants from the host,
  28. resulting in protein-coding differences
  29. * Left unchecked, the host immune system eventually notices these
  30. alloantigens and begins attacking (rejecting) the graft
  31. * Rejection is the major long-term threat to organ allografts
  32. :::
  33. ## Allograft rejection remains a major long-term problem
  34. ![Kidney allograft survival rates in children by transplant year[^kim-marks]](graphics/presentation/kidney-graft-survival.png){ height=65% }
  35. [^kim-marks]:[ Kim & Marks. "Long-term outcomes of children after solid organ transplantation". In: Clinics (2014)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884158/?report=classic)
  36. ## Rejection is treated with immune suppressive drugs
  37. <!-- TODO: Need a graphic, or maybe a table of common drugs +
  38. mechanisms, or a diagram for periodic checking. -->
  39. ::: incremental
  40. * To prevent rejection, a graft recipient must take immune suppressive
  41. drugs for the rest of their life
  42. * The graft is periodically checked for signs of rejection, and immune
  43. suppression dosage is adjusted accordingly
  44. * Immune suppression is a delicate balance: too much leads to immune
  45. compromise; too little leads to rejection.
  46. :::
  47. ## My thesis topics
  48. ### Topic 1: Immune memory
  49. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  50. and memory $\mathsf{CD4}^{+}$ T-cell activation
  51. ### Topic 2: Diagnostics for rejection
  52. Improving array-based diagnostics for transplant rejection by
  53. optimizing data preprocessing
  54. ### Topic 3: Blood profiling during treatment
  55. Globin-blocking for more effective blood RNA-seq analysis in primate
  56. animal model for experimental graft rejection treatment
  57. ## Today's focus
  58. ### \Large Topic 1: Immune memory
  59. \Large
  60. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  61. and memory $\mathsf{CD4}^{+}$ T-cell activation
  62. ## Memory cells: faster, stronger, and more independent
  63. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-A-SVG.png)
  64. ## Memory cells: faster, stronger, and more independent
  65. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-B-SVG.png)
  66. ## Memory cells: faster, stronger, and more independent
  67. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-C-SVG.png)
  68. ## Memory cells: faster, stronger, and more independent
  69. ![Naïve and memory T-cell responses to activation](graphics/presentation/T-cells-D-SVG.png)
  70. ## Memory cells are a problem for immune suppression
  71. <!-- Need graphics? Or maybe just mark this slide as speaker notes for the previous one -->
  72. \large
  73. Compared to naïve cells, memory cells:
  74. \normalsize
  75. * respond to a lower antigen concentration
  76. * respond more strongly at any given antigen concentration
  77. * require less co-stimulation
  78. * are somewhat independent of some types of co-stimulation required by
  79. naïve cells
  80. * evolve over time to respond even more strongly to their antigen
  81. ## Memory cells are a problem for immune suppression
  82. \large
  83. Result:
  84. \normalsize
  85. * Memory cells require progressively higher doses of immune suppresive
  86. drugs
  87. * Dosage cannot be increased indefinitely without compromising the
  88. immune system's ability to fight infection
  89. ## We need a better understanding of immune memory
  90. * Cell surface markers of naïve and memory $\mathsf{CD4}^{+}$ T-cells
  91. are fairly well-characterized
  92. * But internal mechanisms that allow memory cells to respond
  93. differently to the same stimulus (antigen presentation) are not
  94. well-understood
  95. . . .
  96. * A reasonable hypothesis is that some of these mechanisms are
  97. epigenetic: using histone marks or DNA methylation to regulate the
  98. expression of certain genes
  99. * We can test this hypothesis by measuring gene expression (using
  100. RNA-seq) and histone methylation (using ChIP-seq) in naïve and
  101. memory T-cells before and after activation
  102. ## Experimental design
  103. * Separately isolate naïve and memory $\mathsf{CD4}^{+}$ T-cells from
  104. 4 donors
  105. * Activate with CD3/CD28 beads
  106. * Take samples at 4 time points: Day 0 (pre-activation), Day 1 (early
  107. activation), Day 5 (peak activation), and Day 14 (post-activation)
  108. * Do RNA-seq + ChIP-seq for 3 histone marks (H3K4me2, H3K4me3, &
  109. H3K27me3) for each sample.
  110. Data generated by Sarah Lamere, published in GEO as
  111. [GSE73214](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73214)
  112. ## A few intermediate analysis steps are required
  113. ![Flowchart of workflow for data analysis](graphics/CD4-csaw/rulegraphs/rulegraph-all-RASTER100.png)
  114. ## Histone modifications occur on consecutive histones
  115. ![ChIP-seq coverage in IL2 gene[^lamerethesis]](graphics/presentation/LaMere-thesis-fig3.9-SVG-CROP.png){ height=65% }
  116. [^lamerethesis]: Sarah LaMere. "Dynamic epigenetic regulation of CD4 T cell activation and memory formation". PhD thesis. TSRI, 2015.
  117. ## Histone modifications occur on consecutive histones
  118. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-A-SVG.png)
  119. ## Histone modifications occur on consecutive histones
  120. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-B-SVG.png)
  121. ## Histone modifications occur on consecutive histones
  122. ![Strand cross-correlation plots](graphics/presentation/CCF-plots-C-SVG.png)
  123. ## SICER identifies enriched regions across the genome
  124. ![Finding "islands" of coverage with SICER[^sicer]](graphics/presentation/SICER-fig1-SVG.png)
  125. [^sicer]: [Zang et al. “A clustering approach for identification of enriched domains from histone modification ChIP-Seq data”. In: Bioinformatics 25.15 (2009)](https://doi.org/10.1093/bioinformatics/btp340)
  126. ## IDR identifies *reproducible* enriched regions
  127. ![Example irreproducible discovery rate[^idr] score consistency plot](graphics/presentation/IDR-example-CROP-RASTER.png){ height=65% }
  128. [^idr]: [Li et al. “Measuring reproducibility of high-throughput experiments”. In: AOAS (2011)](https://doi.org/10.1214/11-AOAS466)
  129. ## Finding enriched regions across the genome
  130. ![Peak-calling summary statistics](graphics/presentation/RCT-thesis-table2.2-SVG-CROP.png)
  131. ## Each histone mark has an "effective promoter radius"
  132. ![Enrichment of peaks near promoters](graphics/CD4-csaw/Promoter-Peak-Distance-Profile-PAGE1-CROP.pdf)
  133. ## Peaks in promoters correlate with gene expression
  134. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-A-SVG.png)
  135. ## Peaks in promoters correlate with gene expression
  136. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-B-SVG.png)
  137. ## Peaks in promoters correlate with gene expression
  138. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-C-SVG.png)
  139. ## Peaks in promoters correlate with gene expression
  140. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-D-SVG.png)
  141. ## Peaks in promoters correlate with gene expression
  142. ![Expression distributions of genes with and without promoter peaks](graphics/presentation/FPKM-by-Peak-Violin-Plots-Z-SVG.png)
  143. ## The story so far
  144. <!-- TODO: Left column: text; right column: flip through relevant image -->
  145. * H3K4me2, H3K4me3, and H3K27me3 occur on many consecutive histones in
  146. broad regions across the genome
  147. * These enriched regions occur more commonly within a certain radius
  148. of gene promoters
  149. * This "effective promoter radius" is consistent across all samples
  150. for a given histone mark, but differs between histone marks
  151. * Presence or absence of a peak within this radius is correlated with
  152. gene expression
  153. . . .
  154. Next: Does the position of a histone modification within a gene
  155. promoter matter to that gene's expression, or is it merely the
  156. presence or absence anywhere within the promoter?
  157. ## H3K4me2 promoter neighborhood K-means clusters
  158. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  159. ## H3K4me2 promoter neighborhood cluster PCA
  160. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-PCA-CROP.png)
  161. ## H3K4me2 promoter neighborhood cluster expression
  162. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-expression-CROP.png)
  163. ## H3K4me3 promoter neighborhood K-means clusters
  164. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-clusters-CROP.png)
  165. ## H3K4me3 promoter neighborhood cluster PCA
  166. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-PCA-CROP.png)
  167. ## H3K4me3 promoter neighborhood cluster expression
  168. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-expression-CROP.png)
  169. ## H3K27me3 promoter neighborhood K-means clusters
  170. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-clusters-CROP.png)
  171. ## H3K27me3 promoter neighborhood cluster PCA
  172. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-PCA-CROP.png)
  173. ## H3K27me3 promoter neighborhood cluster expression
  174. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-expression-CROP.png)
  175. ## What have we learned?
  176. ### H3K4me2 & H3K4me3
  177. * Peak closer to promoter $\Rightarrow$ more likely gene is highly
  178. expressed
  179. * Slightly asymmetric in favor of peaks downstream of TSS
  180. . . .
  181. ### H3K27me3
  182. * Depletion of H3K27me3 at TSS associated with elevated gene
  183. expression
  184. * Enrichment of H3K27me3 upstream of TSS even more strongly associated
  185. with elevated expression
  186. * Other coverage profiles not associated with elevated expression
  187. ## Differential modification disappears by Day 14
  188. ![Differential modification between naïve and memory samples at each time point](graphics/presentation/RCT-thesis-table2.4-A-SVG-CROP.png)
  189. ## Differential modification disappears by Day 14
  190. ![Differential modification between naïve and memory samples at each time point](graphics/presentation/RCT-thesis-table2.4-B-SVG-CROP.png)
  191. ## Convergence at Day 14 H3K4me2
  192. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-promoter-PCA-group-CROP.png)
  193. ## Convergence at Day 14 H3K4me3
  194. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-promoter-PCA-group-CROP.png)
  195. ## Convergence at Day 14 H3K27me3
  196. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-promoter-PCA-group-CROP.png)
  197. ## Convergence at Day 14 RNA-seq (PC 2 & 3)
  198. ![(Insert figure legend)](graphics/CD4-csaw/RNA-seq/PCA-final-23-CROP.png)
  199. ## MOFA identifies shared variation across all 4 data sets
  200. ![(Insert figure legend)](graphics/CD4-csaw/MOFA-varExplaiend-matrix-CROP.png)
  201. ## MOFA shared variation captures convergence pattern
  202. ![(Insert figure legend)](graphics/CD4-csaw/MOFA-LF-scatter-small.png)
  203. ## What have we learned?
  204. * Almost no differential modification observed between naïve and
  205. memory at Day 14, despite plenty of differential modification at
  206. earlier time points.
  207. * RNA-seq data and all 3 histone marks' ChIP-seq data all show
  208. "convergence" between naïve and memory by Day 14 in the first 2 or 3
  209. principal coordinates.
  210. * MOFA captures this convergence pattern in one of the latent factors,
  211. indicating that this is a shared pattern across all 4 data sets.
  212. <!-- ## Slide -->
  213. <!-- ![(Insert figure legend)](graphics/CD4-csaw/LaMere2016_fig8.pdf) -->
  214. ## Takeaway 1: Each histone mark has an "effective promoter radius"
  215. * H3K4me2, H3K4me3, and H3K27me3 ChIP-seq reads are enriched in broad
  216. regions across the genome, representing areas where the histone
  217. modification is present
  218. * These enriched regions occur more commonly within a certain radius
  219. of gene promoters
  220. * This "effective promoter radius" is specific to each histone mark
  221. * Presence or absence of a peak within this radius is correlated with
  222. gene expression
  223. ## Takeaway 2: Peak position within the promoter is important
  224. * H3K4me2 and H3K4me3 peaks are more strongly associated with elevated
  225. gene expression the closer they are to the TSS, with a slight bias
  226. toward downstream peaks.
  227. * H3K27me3 depletion at the TSS and enrichement upstream are both
  228. associated with elevated expression, while other patterns are not.
  229. * In all histone marks, position of modification within promoter
  230. appears to be an important factor in association with gene
  231. expression
  232. ## Takeaway 3: Expression & epigenetic state both converge at Day 14
  233. * At Day 14, almost no differential modification observed between
  234. naïve and memory cells
  235. * Naïve and memory converge visually in PCoA plots
  236. * Convergence is a shared pattern of variation across all 3 histone
  237. marks and gene expression
  238. * This is consistent with the hypothesis that the naïve cells have
  239. differentiated into a more memory-like phenotype by day 14.